Global Multiple System Atrophy Market Pipeline Review, H1 2018

1
Global Multiple System Atrophy Market Pipeline
Review, H1 2018
2

• SUMMARY
• Global Markets Direct's Pharmaceutical and
  Healthcare latest pipeline guide Multiple System
  Atrophy (MSA or Shy-Drager Syndrome or
  Multi-System Degeneration)-Pipeline Review, H1
  2018, provides comprehensive information on the
  therapeutics under development for Multiple
  System Atrophy (MSA or Shy-Drager Syndrome or
  Multi-System Degeneration) (Central Nervous
  System), complete with analysis by stage of
  development, drug target, mechanism of action
  (MoA), route of administration (RoA) and molecule
  type.
• The guide covers the descriptive pharmacological
  action of the therapeutics, its complete research
  and development history, and latest news and
  press releases.

3

• Multiple System Atrophy
• Global Markets Direct's latest Pharmaceutical
  and Healthcare disease pipeline guide Multiple
  System Atrophy (MSA or Shy-Drager Syndrome or
  Multi-System Degeneration)-Pipeline Review, H1
  2018 provides an overview of the Multiple System
  Atrophy (MSA or Shy-Drager Syndrome or
  Multi-System Degeneration) (Central Nervous
  System) pipeline landscapes.
• Multiple system atrophy (MSA) or Shy-Drager
  syndrome is a neurological disorder that impairs
  the body's involuntary functions (blood pressure,
  heart rate, bladder function, and digestion).
  Symptoms include rigid muscles, bradykinesia,
  Tremors, dysarthria, dysphagia, constipation,
  incontinence, and irregular heartbeat. Treatment
  is aimed at relieving symptoms with
  anti-Parkinson's medications.

4

• 
  Multiple System Atrophy
• Global Markets Direct's Pharmaceutical and
  Healthcare latest pipeline guide Multiple System
  Atrophy (MSA or Shy-Drager Syndrome or
  Multi-System Degeneration)-Pipeline Review, H1
  2018, provides comprehensive information on the
  therapeutics under development for Multiple
  System Atrophy (MSA or Shy-Drager Syndrome or
  Multi-System Degeneration) (Central Nervous
  System), complete with analysis by stage of
  development, drug target, mechanism of action
  (MoA), route of administration (RoA) and molecule
  type. The guide covers the descriptive
  pharmacological action of the therapeutics, its
  complete research and development history, and
  latest news and press releases.

5

• Multiple System Atrophy
• The Multiple System Atrophy (MSA or Shy-Drager
  Syndrome or Multi-System Degeneration) (Central
  Nervous System) pipelines guides also reviews of
  key players involved in therapeutic development
  for Multiple System Atrophy (MSA or Shy-Drager
  Syndrome or Multi-System Degeneration) and
  features dormant and discontinued projects.
• The guide covers therapeutics under Development
  by Companies /Universities /Institutes, the
  molecules developed by Companies in Phase I,
  Preclinical and Discovery stages are 4, 6 and 1
  respectively.

6

• Browse Full Market Report
• Multiple System Atrophy (MSA or Shy-Drager
  Syndrome or Multi-System Degeneration)-Pipeline
  Review, H1 2018
• Related reports
• Multiple System Atrophy (MSA or Shy-Drager
  Syndrome or Multi-System Degeneration)-Pipeline
  Review, H2 2017
• Multiple System Atrophy (MSA or Shy-Drager
  Syndrome or Multi-System Degeneration)-Pipeline
  Review, H2 2016

7
About ken research

• Ken Research provides bespoke industry
  intelligence, equity research reports and
  business consulting services on gamut of sectors
  across the globe. We use advanced information
  management tools, sophisticated analytical
  systems and methodologies to help our clients
  with crucial industry information for decision
  making.
• As a leading Online Market Research Report
  Seller, Ken Research act as a platform for
  accessing statistics, forecast, business
  insights, Ideas, concepts and much more.

8

• Contact Us
• Ken Research
• Ankur Gupta, Head Marketing Communications
• sales_at_kenresearch.com
• 91-9015378249

9
(No Transcript)